Skip to main content

Advertisement

SpringerLink
Log in

Risk of Subsequent Primary Tumor Development in Melanoma Patients

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Incidence of subsequent malignant tumor development in 740 patients with primary cutaneous melanoma verified between 2006 and 2010 at the Semmelweis University was studied retrospectively and was compared to data of sex and age matched Hungarian population. The follow-up period was 1499 person-years for the whole group from the diagnosis of index melanoma with an average of 2 years. Standardized incidence rate (SIR) was established as the ratio of observed and expected values. The risk of all subsequent malignancies was 15- and 10-fold higher in males (SIR: 15.42) and in females (SIR: 10.55) with melanoma, than in the general population. The increased cancer risk resulted mainly from the significantly higher skin tumor development: SIR values were 160.39 and 92.64 for additional invasive melanoma and 342.28 and 77.04 for subsequent in situ melanoma in males and females, respectively. Non-melanoma skin cancers also notably contributed to the higher risk, the SIR was elevated in both genders to the same extent (males: 17.12, females: 17.55). The risk was also significantly higher for extracutaneous tumor development like chronic lymphocytic leukemia, colon and kidney cancer (both genders), non-Hodgkin’s lymphoma, cervical cancer (females), and bladder carcinoma (males). These data underline the importance of patient education and the necessity of frequent medical follow up, including a close-up dermatological screening of melanoma survivors for further malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

ALL:

Acute lymphocytic leukemia

CLL:

Chronic lymphocytic leukemia

CI:

Confidence interval

E:

Expected value

EAR:

Excess absolute risk

MM:

Malignant melanoma

NHL:

Non-Hodgkin’s lymphoma

NMSC:

Non-melanoma skin cancer

NOS:

Not otherwise specified

O:

Observed value

SEER:

Surveillance Epidemiology and End Results

SIR:

Standardized incidence rate

PYR:

Person year

UV:

Ultraviolet

References

  1. Wassberg C, Thörn M, Yuen J, Ringborg U, Hakulinen T (1996) Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer 73:255–259

    Article  PubMed  CAS  Google Scholar 

  2. Levi F, LaVecchia C, Randimbison L, Te VC, Erler G (1997) Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer Suppl 72:776–779

    Article  CAS  Google Scholar 

  3. Wassberg C, Thorn M, Yuen J, Hakulinen T, Ringborg U (1999) Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer 83:314–317

    Article  PubMed  CAS  Google Scholar 

  4. Kroumpouzos G, Konstadoulakis MM, Cabral H, Karakousis CP (2000) Risk of basal cell and squamous cell carcinoma in persons with prior cutaneous melanoma. Dermatol Surg 26:547–550

    Article  PubMed  CAS  Google Scholar 

  5. Goggins WB, Finkelstein DM, Tsao H (2001) Evidence for an association between cutaneous melanoma and non-Hodgkin lymphoma. Cancer 91:874–880

    Article  PubMed  CAS  Google Scholar 

  6. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M (2001) Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 145:981–985

    Article  PubMed  CAS  Google Scholar 

  7. Crocetti E, Carli P (2004) Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur J Cancer Prev 13:33–37

    Article  PubMed  CAS  Google Scholar 

  8. Lens MB, Newton-Bishop JA (2005) An association between cutaneous melanoma and non-Hodgkin’s lymphoma: pooled analysis of published data with a review. Ann Oncol 16:460–465

    Article  PubMed  CAS  Google Scholar 

  9. Wu YH, Kim GH, Wagner JD, Hood AF, Chuang TY (2006) The association between malignant melanoma and noncutaneous malignancies. Int J Dermatol 45:529–534

    Article  PubMed  Google Scholar 

  10. Freedman DM, Miller BA, Tucker MA (2006) New malignancies following melanoma of skin, eye melanoma, and nonmelanoma eye cancer. In: Curtis RE, Freedman DM, Ron E et al (eds) New malignancies among cancer survivors: SEER cancer registries, 1973-2000. National Cancer Institute, Bethesda

    Google Scholar 

  11. Crocetti E, Guzzinati S, Paci E, Falcini F, Zanetti R, Vercelli M et al (2008) The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res 18:230–234

    Article  PubMed  Google Scholar 

  12. Cantwell MM, Murray LJ, Catney D, Donnelly D, Autier P, Boniol M et al (2009) Second primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer 100:174–177

    Article  PubMed  CAS  Google Scholar 

  13. Spanogle JP, Clarke CA, Aroner S, Swetter SM (2010) Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 62:757–767

    Article  PubMed  Google Scholar 

  14. Bradford PT, Freedman DM, Goldstein AM, Tucker MA (2010) Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 146:265–272

    Article  PubMed  Google Scholar 

  15. Balamurugan A, Rees JR, Kosary C, Rim SH, Li J, Stewart SL (2011) Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J Am Acad Dermatol 65(5 Suppl 1):69–77

    Google Scholar 

  16. Bhatia S, Estrada-Batres L, Maryon T, Bogue M, Chu D (1999) Second primary tumors in patients with cutaneous malignant melanoma. Cancer 86:2014–2020

    Article  PubMed  CAS  Google Scholar 

  17. Wolff J, Wollina U (2000) Second malignancies in melanoma patients in Thuringia. J Eur Acad Dermatol Venereol 14:479–483

    Article  PubMed  CAS  Google Scholar 

  18. Manganoni AM, Pavoni L, Farisoglio C, Sereni E, Chiudinelli M, Calzavara-Pinton P (2012) Association between multiple cutaneous melanoma and other primary neoplasms. Clin Exp Dermatol 37:857–861

    Article  PubMed  CAS  Google Scholar 

  19. National Cancer Registry (2001-2010) National Institute of Oncology http://www.honcology.hu/portal/page/portal/OOI/MEDICAL_ATTENDANCE/medical_departments/MD_901/Statisztika

  20. Rothman KJ, Boice JD (1979) Epidemiologic analysis with a programmable calculator (NIH publication 79-1649). US Government Printing Office, Washington DC

    Google Scholar 

  21. Pearson K (1900) On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philos Mag 50:157–175

    Google Scholar 

  22. Yates F (1934) Contingency table involving small numbers and the χ 2 test. Suppl J R Stat Soc 1:217–235

    Article  Google Scholar 

  23. Ward KA, Lazovich D, Hordinsky MK (2012) Germline melanoma susceptibility and prognostic genes: a review of the literature. J Am Acad Dermatol 67:1055–1067

    Article  PubMed  Google Scholar 

  24. Read J (2013) Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. Australas J Dermatol. doi:10.1111/ajd.12013

    PubMed  Google Scholar 

  25. Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 2013 Feb 13. [Epub ahead of print]

  26. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O et al (2012) RAS mutations in cutaneous squamous-cell carcionomas in patients treated with BRAF inhibitors. N Engl J Med 366:207–215

    Article  PubMed  CAS  Google Scholar 

  27. Chapman PB et al (2012) Development of colonic adenomas and gastric polyps in BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell Melanoma Res 25:847

    Google Scholar 

  28. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T et al (2012) Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316–2321

    Article  PubMed  CAS  Google Scholar 

  29. Smalley KS, Sondak VK (2013) Targeted therapy for melanoma: is double hitting a home run? Nat Rev Clin Oncol 10:5–6

    Article  PubMed  CAS  Google Scholar 

  30. Grant WB (2012) Ultraviolet exposure and non-Hodgkin’s lymphoma: beneficial and adverse effects? Cancer Causes Control 23:653–655

    Article  PubMed  Google Scholar 

  31. Bertrand KA, Chang ET, Abel GA, Zhang SM, Spiegelman D, Qureshi AA et al (2011) Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses’ Health Study. Cancer Causes Control 22:1731–1741

    Article  PubMed  Google Scholar 

  32. Grant WB (2012) Update on evidence that support a role of solar ultraviolet-B irradiance in reducing cancer risk. Anticancer Agents Med Chem 13:140–146

    Google Scholar 

  33. Grant WB (2002) An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 94:272–281

    Article  PubMed  Google Scholar 

  34. Grant WB, Garland CF (2002) The association of solar ultraviolet-B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res 26:2687–2699

    Google Scholar 

  35. Boscoe FP, Schymura MJ (2006) Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993–2002. BMC Cancer 6:264

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The work was co-financed by OTKA K73296 and TÁMOP-4.2.1/B-09/1/KMR-2010-0001. JFL was partially supported by the TÁMOP-4.2.2.C-11/1/KONV-2012-0001 project. (The project is implemented through the New Hungary Development Plan, co-financed by the European Social Fund and the European Regional Development Fund.)

Author information

Authors and Affiliations

  1. Department of Dermatoloy, Dermatooncology and Venerology, Semmelweis University, 1085 Mária street 41, Budapest, Hungary

    Veronika Tóth, Zsófia Hatvani, Beáta Somlai, Judit Hársing & Sarolta Kárpáti

  2. Department of Computer Science, University of Debrecen, 4028 Kassai street 26, Debrecen, Hungary

    János F. László

Authors
  1. Veronika Tóth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zsófia Hatvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beáta Somlai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Judit Hársing
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. János F. László
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sarolta Kárpáti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Veronika Tóth.

Additional information

Veronika Tóth and Zsófia Hatvani equally contributed to the article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tóth, V., Hatvani, Z., Somlai, B. et al. Risk of Subsequent Primary Tumor Development in Melanoma Patients. Pathol. Oncol. Res. 19, 805–810 (2013). https://doi.org/10.1007/s12253-013-9647-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-013-9647-8

Keywords

Search

Navigation